作为公司的三位核心人物之一,荣昌生物(688331.SH,09995.HK)首席战略官何如意在农历新年的第一周提交了辞职报告。 在近年来大热的ADC(抗体药物偶联物)赛道中,荣昌生物曾经是领跑的明星公司,公司旗下的核心产品之一的维迪西妥单抗也曾创下过单款药物海外授权的纪录。但荣昌生物在研发上的高投入正在持续消耗现金流,尽管这笔交易带来的2亿美元首付款让公司当年短暂实现盈利,但公司五年累计亏损约...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.